Ezrin Expression Is an Independent Prognostic Factor in Gastro-intestinal Cancers

Journal of Gastrointestinal Surgery

Volumn 17, Issue 12, 2013, Pages 2082-2091

  Arumugam, Prabhu ^a,b   Partelli, Stefano ^a,b,c   Coleman, Stacey J ^a   Cataldo, Ivana ^d   Beghelli, Stefania ^d   Bassi, Claudio ^d   Wijesuriya, Nilukushi ^b   Aleong, Jo Anne Chin ^b   Froeling, Fieke E M ^a   Scarpa, Aldo ^d   Kocher, Hemant M ^a,b  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b ROYAL LONDON HOSPITAL   (United Kingdom)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

Author keywords

Ampullary cancer; Colorectal cancer; Survival

Indexed keywords

CYTOSKELETON PROTEIN; EZRIN;

ARTICLE; BILE DUCT TUMOR; DISEASE FREE SURVIVAL; GASTROINTESTINAL TUMOR; HUMAN; IMMUNOPRECIPITATION; LIVER TUMOR; METABOLISM; METASTASIS; MORTALITY; MULTIVARIATE ANALYSIS; PATHOLOGY; PROGNOSIS; VATER PAPILLA; WESTERN BLOTTING;

AMPULLA OF VATER; BLOTTING, WESTERN; COMMON BILE DUCT NEOPLASMS; CYTOSKELETAL PROTEINS; DISEASE-FREE SURVIVAL; GASTROINTESTINAL NEOPLASMS; HUMANS; IMMUNOPRECIPITATION; LIVER NEOPLASMS; MULTIVARIATE ANALYSIS; PROGNOSIS;

EID: 84888299971     PISSN: 1091255X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11605-013-2384-1     Document Type: Article

References (26)

1. Curto M, McClatchey AI. Ezrin.a metastatic detERMinant? Cancer Cell. 2004 Feb;5(2): 113-4.
2. Yu H, Zhang Y, Ye L, Jiang WG. The FERM family proteins in cancer invasion and metastasis. Front Biosci. 2011;16: 1536-50.
3. Hughes SC, Fehon RG. Understanding ERM proteins-the awesome power of genetics finally brought to bear. Curr Opin Cell Biol. 2007 Feb;19(1): 51-6.
4. Kocher HM, Sandle J, Mirza TA, Li NF, Hart IR. Ezrin interacts with Cortactin to form podosomal rosettes in pancreatic cancer cells. Gut. 2009;58(2): 271-84.
5. Froeling FE, Mirza TA, Feakins RM, Seedhar A, Elia G, Hart IR, Kocher HM. Organotypic culture model of pancreatic cancer demonstrates that stromal cells modulate E-cadherin, beta-catenin, and Ezrin expression in tumor cells. Am J Pathol. 2009 Aug;175(2): 636-48.
6. Elzagheid A, Korkeila E, Bendardaf R, Buhmeida A, Heikkila S, Vaheri A, Syrjanen K, Pyrhonen S, Carpen O. Intense cytoplasmic ezrin immunoreactivity predicts poor survival in colorectal cancer. Hum Pathol. 2008 Dec;39(12): 1737-43.
7. Patara M, Santos EM, Coudry RD, Soares FA, Ferreira FO, Rossi BM. Ezrin Expression as a Prognostic Marker in Colorectal Adenocarcinoma. Pathol Oncol Res. 2011 Apr 5;17(4): 827-833.
8. Wang HJ, Zhu JS, Zhang Q, Sun Q, Guo H. High level of ezrin expression in colorectal cancer tissues is closely related to tumor malignancy. World J Gastroenterol. 2009 Apr 28;15(16): 2016-9.
9. Hustinx SR, Fukushima N, Zahurak ML, Riall TS, Maitra A, Brosens L, Cameron JL, Yeo CJ, Offerhaus GJ, Hruban RH, Goggins M. Expression and prognostic significance of 14-3-3sigma and ERM family protein expression in periampullary neoplasms. Cancer Biol Ther. 2005 May;4(5): 596-601.
10. Falconi M, Crippa S, Dominguez I, Barugola G, Capelli P, Marcucci S, Beghelli S, Scarpa A, Bassi C, Pederzoli P. Prognostic relevance of lymph node ratio and number of resected nodes after curative resection of ampulla of Vater carcinoma. Ann Surg Oncol. 2008 Nov;15(11): 3178-86.
11. Partelli S, Mukherjee S, Mawire K, Hutchins RR, Abraham AT, Bhattacharya S, Kocher HM. Larger hepatic metastases are more frequent with N0 colorectal tumours and are associated with poor prognosis: implications for surveillance. Int J Surg. 2010;8(6): 453-7.
12. Froeling FE, Feig C, Chelala C, Dobson R, Mein CE, Tuveson DA, Clevers H, Hart IR, Kocher HM. Retinoic Acid-Induced Pancreatic Stellate Cell Quiescence Reduces Paracrine Wnt-beta-Catenin Signaling to Slow Tumor Progression. Gastroenterology. 2011 Oct;141(4): 1486-97.
13. Holgren C, Dougherty U, Edwin F, Cerasi D, Taylor I, Fichera A, Joseph L, Bissonnette M, Khare S. Sprouty-2 controls c-Met expression and metastatic potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. Oncogene. 2010 Sep 23;29(38): 5241-53.
14. Khanna C, Wan X, Bose S, Cassaday R, Olomu O, Mendoza A, Yeung C, Gorlick R, Hewitt SM, Helman LJ. The membrane-cytoskeleton linker ezrin is necessary for osteosarcoma metastasis. Nat Med. 2004 Feb;10(2): 182-6.
15. Yu Y, Khan J, Khanna C, Helman L, Meltzer PS, Merlino G. Expression profiling identifies the cytoskeletal organizer ezrin and the developmental homeoprotein Six-1 as key metastatic regulators. Nat Med. 2004 Feb;10(2): 175-81.
16. Elliott BE, Meens JA, SenGupta SK, Louvard D, Arpin M. The membrane cytoskeletal crosslinker ezrin is required for metastasis of breast carcinoma cells. Breast Cancer Res. 2005;7(3): R365-73.
17. Nowak D, Mazur AJ, Popow-Wozniak A, Radwanska A, Mannherz HG, Malicka-Blaszkiewicz M. Subcellular distribution and expression of cofilin and ezrin in human colon adenocarcinoma cell lines with different metastatic potential. Eur J Histochem. 2010;54(2): e14.
18. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. J Cell Sci. 2011 Jun 15;123(Pt 12): 2135-43.
19. Moosmann N, von Weikersthal LF, Vehling-Kaiser U, Stauch M, Hass HG, Dietzfelbinger H, Oruzio D, Klein S, Zellmann K, Decker T, Schulze M, Abenhardt W, Puchtler G, Kappauf H, Mittermuller J, Haberl C, Schalhorn A, Jung A, Stintzing S, Heinemann V. Cetuximab plus capecitabine and irinotecan compared with cetuximab plus capecitabine and oxaliplatin as first-line treatment for patients with metastatic colorectal cancer: AIO KRK-0104-a randomized trial of the German AIO CRC study group. J Clin Oncol. 2011 Mar 10;29(8): 1050-8.
20. Rebillard A, Jouan-Lanhouet S, Jouan E, Legembre P, Pizon M, Sergent O, Gilot D, Tekpli X, Lagadic-Gossmann D, Dimanche-Boitrel MT. Cisplatin-induced apoptosis involves a Fas-ROCK-ezrin-dependent actin remodelling in human colon cancer cells. Eur J Cancer. 2010 May;46(8): 1445-55.
21. Yao Y, Jia XY, Tian HY, Jiang YX, Xu GJ, Qian QJ, Zhao FK. Comparative proteomic analysis of colon cancer cells in response to oxaliplatin treatment. Biochim Biophys Acta. 2009 Oct;1794(10): 1433-40.
22. Sahai E, Marshall CJ. Differing modes of tumour cell invasion have distinct requirements for Rho/ROCK signalling and extracellular proteolysis. Nat Cell Biol. 2003 Aug;5(8): 711-9.
23. Chen Y, Wang D, Guo Z, Zhao J, Wu B, Deng H, Zhou T, Xiang H, Gao F, Yu X, Liao J, Ward T, Xia P, Emenari C, Ding X, Thompson W, Ma K, Zhu J, Aikhionbare F, Dou K, Cheng SY, Yao X. Rho kinase phosphorylation promotes ezrin-mediated metastasis in hepatocellular carcinoma. Cancer Res. 2011 Mar 1;71(5): 1721-9.
24. Orsatti L, Forte E, Tomei L, Caterino M, Pessi A, Talamo F. 2-D Difference in gel electrophoresis combined with Pro-Q Diamond staining: a successful approach for the identification of kinase/phosphatase targets. Electrophoresis. 2009 Jul;30(14): 2469-76.
25. Forte E, Orsatti L, Talamo F, Barbato G, De Francesco R, Tomei L. Ezrin is a specific and direct target of protein tyrosine phosphatase PRL-3. Biochim Biophys Acta. 2008 Feb;1783(2): 334-44.
26. Saha S, Bardelli A, Buckhaults P, Velculescu VE, Rago C, St Croix B, Romans KE, Choti MA, Lengauer C, Kinzler KW, Vogelstein B. A phosphatase associated with metastasis of colorectal cancer. Science. 2001 Nov 9;294(5545): 1343-6.